Stockholders' Equity (Details) - USD ($) |
1 Months Ended | 3 Months Ended | 6 Months Ended | |||
|---|---|---|---|---|---|---|
Nov. 30, 2020 |
Jun. 30, 2021 |
Jun. 30, 2020 |
Jun. 30, 2021 |
Jun. 30, 2020 |
Dec. 31, 2020 |
|
| Stockholders' Equity (Details) [Line Items] | ||||||
| Stock issued in connection with cashless exercise of warrants | 70,269 | |||||
| Cashless exercise of warrants | 95,286 | |||||
| Preferred stock authorized | 2,000,000 | 2,000,000 | 2,000,000 | |||
| Preferred shares was converted description | During the six months ended June 30, 2021, 50,000 Series C-3 preferred shares were converted into 100,000 shares of the Company’s common stock by an unrelated party and 10,001 Series G preferred shares were converted into 556,069 shares of the Company’s common stock by a related party. | |||||
| Weighted Average Exercise Price (in Dollars per share) | $ 7.72 | $ 7.72 | $ 7.22 | |||
| Compensation expense (in Dollars) | $ 1,010,000 | $ 693,000 | $ 2,742,000 | $ 1,362,000 | ||
| Unrecognized compensation expense (in Dollars) | $ 8,585,000 | $ 8,585,000 | ||||
| Weighted average remaining contractual life | 1 year 7 months 6 days | |||||
| Stock option awards vested | 410,000 | 410,000 | ||||
| Dividend yield | 0.00% | |||||
| Expected term | 2 years | |||||
| Common stock cashless exercise | 95,286 | |||||
| Weighted average remaining contractual life | 7 years 1 month 6 days | |||||
| Restricted Stock Units [Member] | ||||||
| Stockholders' Equity (Details) [Line Items] | ||||||
| Compensation expense (in Dollars) | $ 3,000 | $ 10,000 | ||||
| Issuance of vested restricted stock | 2,385 | |||||
| Stock Options [Member] | ||||||
| Stockholders' Equity (Details) [Line Items] | ||||||
| stock options granted | 1,389,700 | |||||
| Weighted Average Exercise Price (in Dollars per share) | $ 8.48 | $ 8.48 | ||||
| Employees [Member] | ||||||
| Stockholders' Equity (Details) [Line Items] | ||||||
| Expected term | 5 years | |||||
| Non-employees [Member] | ||||||
| Stockholders' Equity (Details) [Line Items] | ||||||
| Expected term | 10 years | |||||
| Series C-3 preferred shares [Member] | ||||||
| Stockholders' Equity (Details) [Line Items] | ||||||
| Number of shares converted to common stock | 50,000 | |||||
| Series G preferred shares [Member] | ||||||
| Stockholders' Equity (Details) [Line Items] | ||||||
| Number of shares converted to common stock | 10,001 | |||||
| Common Stock [Member] | ||||||
| Stockholders' Equity (Details) [Line Items] | ||||||
| New ATM agreement, description | the Company filed a new registration statement, under which the Company could issue and sell up to an aggregate of $100.0 million of shares of its common stock, $0.001 par value per share. On November 27, 2020, the Company entered into an Amended and Restated At Market Issuance Sales Agreement (“Amended Sales Agreement”) with B. Riley FBR Inc. (“B.Riley”) and Needham & Company, LLC (“Needham”), together with B. Riley, acting as sales agents (“Sales Agent”). The Amended Sales Agreement relates to the sale of shares of up to $25.0 million of the Company’s common stock under its ATM program, of which the Company may issue and sell common stock from time to time through the Sales Agent, subject to limitations imposed by the Company and subject to the Sales Agent’s acceptance, such as the number or dollar amount of shares registered under the registration statement to which the offering relates. The Sales Agent is entitled to a commission of up to 3% of the gross proceeds from the sale of common stock sold under the ATM program. At December 31, 2020, the Company had approximately $17.8 million available under the Amended Sales Agreement and $75.0 million available under its current shelf registration for the issuance of equity, debt or equity-linked securities unrelated to the Amended Sales Agreement. On February 5, 2021, the Company allocated to its ATM program an additional $25.0 million of the remaining $75.0 million available under its shelf registration statement. Giving effect to the additional $25.0 million, plus the $17.8 million available at December 31, 2020, the Company had a total of $42.8 million available under the ATM program. During the six months ended June 30, 2021 and 2020, the Company sold an aggregate of 3,737,862 and 368,144 shares of its common stock under the ATM program, respectively, and realized net proceeds of $41,456,000 and $2,470,000, respectively. As of June 30, 2021, the Company has no available balance under its ATM program and it has $50.0 million available under its current shelf registration for the issuance of equity, debt or equity-linked securities. | |||||
| Common stock issued an aggregate | 656,069 | |||||
| Net proceeds | 31,407 | 91,500 | ||||
| Net proceeds value of cash exercise of warrants (in Dollars) | $ 165,000 | |||||
| Net proceeds value of cash exercise of warrants (in Dollars) | $ 412,000 | |||||
| Exercise of stock options | 32,734 | |||||
| Net proceeds (in Dollars) | $ 137,000 | |||||
| Common Stock [Member] | Board of directors [Member] | ||||||
| Stockholders' Equity (Details) [Line Items] | ||||||
| Common stock issued an aggregate | 2,385 | |||||
| Preferred Stock [Member] | ||||||
| Stockholders' Equity (Details) [Line Items] | ||||||
| Preferred stock authorized to issue | 2,000,000 | |||||
| Preferred stock authorized | 2,000,000 | 2,000,000 | ||||
| Preferred stock par value (in Dollars per share) | $ 0.001 | $ 0.001 | ||||
| Warrant [Member] | ||||||
| Stockholders' Equity (Details) [Line Items] | ||||||
| Weighted Average Exercise Price (in Dollars per share) | $ 5.25 | $ 5.25 | ||||
| Aggregate of common stocks cash exercise | 31,407 | 91,500 | ||||
| Stock issued in connection with warrants exercised (in Dollars) | $ 165,000 | $ 412,000 | ||||
| Aggregate of common stocks cashless exercise | 70,269 | |||||
| Outstanding warrants | 56,455 | |||||
| Weighted average remaining contractual life | 1 year 1 month 9 days | |||||